For the quarter ending 2025-09-30, CATX had -$2,087K decrease in cash & cash equivalents over the period. -$18,284K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -25,969 | -39,662 |
| Net accretion of discounts on available-for-sale securities | -558 | -1,765 |
| Depreciation and amortization expense | 775 | 1,465 |
| Accrued interest on held-to-maturity investments | 0 | 0 |
| Share-based compensation | 2,156 | 4,501 |
| Other noncash expense, net | -14 | -222 |
| Accounts receivable, net | -46 | 109 |
| Interest receivable | 19 | 286 |
| Inventory | 0 | 0 |
| Prepaid expenses and other current assets | 10 | -259 |
| Accounts payable and accrued expenses | 5,541 | -4,548 |
| Deferred income | 0 | -1,400 |
| Accrued personnel expenses | 1,674 | -441 |
| Other noncurrent liabilities | 58 | 229 |
| Net cash (used in) provided by operating activities | -16,292 | -41,535 |
| Additions to property and equipment | 1,992 | 5,682 |
| Additions to other assets | 39 | 45 |
| Purchases of held-to-maturity securities | 0 | 0 |
| Proceeds from held-to-maturity securities | 0 | 0 |
| Purchases of available-for-sale securities | 32,131 | 67,094 |
| Maturities of available-for-sale securities | 48,154 | 71,520 |
| Net cash provided by (used in) investing activities | 13,992 | -1,301 |
| Repayment of note payable | 13 | 26 |
| Proceeds from sales of common stock, pursuant to exercise of warrants, net | 0 | 0 |
| Proceeds from sales of common stock, pursuant to exercise of options | 226 | 145 |
| Proceeds from the issuance of common stock and pre-funded warrants, net | 0 | 0 |
| Proceeds from the sale of common stock pursuant to at-the-market offering, net | 0 | 9,986 |
| Net cash provided by financing activities | 213 | 10,105 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -2,087 | -32,731 |
| Cash and cash equivalents at beginning of period | 61,580 | - |
| Cash and cash equivalents at end of period | 26,762 | - |
Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc. (CATX)